Gold has topped $4,200. Here’s why Yardeni thinks the rally could go even higher.
SR One Capital Management, along with Simeon George, reported purchasing shares of Zenas BioPharma Inc (NASDAQ:ZBIO) on October 9, 2025. The purchases, made at a price of $19 per share, totaled $2399985. The stock, currently trading at $25.76, has shown remarkable momentum with a 27% gain in the past week. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $24 to $45.
The transactions involved the acquisition of 63,158 shares and 63,157 shares of common stock. The company, now valued at $1.12 billion, maintains a strong balance sheet with more cash than debt. Want deeper insights? InvestingPro offers 11 additional investment tips for ZBIO.
In other recent news, Zenas Biopharma has entered a significant licensing agreement with InnoCare Pharma, granting Zenas global rights to develop and commercialize three autoimmune product candidates, including orelabrutinib, a BTK inhibitor in Phase 3 development for multiple sclerosis. The agreement involves Zenas paying InnoCare up to $100 million in cash for upfront and near-term milestone payments, alongside up to 7 million shares of Zenas common stock. The total potential value of the deal exceeds $2 billion when considering development, regulatory, and commercial milestones. H.C. Wainwright has maintained a Buy rating on Zenas Biopharma, citing the company’s pipeline expansion following this agreement. The firm has set a price target of $30.00 for Zenas Biopharma. Meanwhile, Zeta Network Group has announced a strategic partnership with SOLV Foundation to enhance its Bitcoin-centric financial initiatives. This partnership will utilize SOLV’s platform, which holds $2.5 billion in total value locked, to optimize Zeta Network Group’s Bitcoin holdings. The Bitcoin assets will be managed under the custody of a regulated third-party custodian to ensure transparency and auditability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.